Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese pharmaceutical firm Eisai said it would cut about 25% jobs across various US functions as part of a realignment to create a more efficient and focused company.
Subscribe to our email newsletter
The company’s US unit Eisai employs about 1,800 people and its operations include research and development, manufacturing, sales and marketing and administrative functions.
Eisai chairman and CEO Yuji Matsue said: "The actions we are taking will ensure Eisai stays competitive in a rapidly changing business environment.
"Eisai remains fully committed to the U.S. market and will continue to serve the needs of patients and their families by developing and marketing important new treatments that help to satisfy unmet medical needs.
"Through this realignment, we will be able to redeploy our resources to support the development of our priority late-stage compounds and our current product portfolio."
The new structure is expected to be in place by 01 May 2015 and the company does not have plans to close any of its main offices or facilities.
Eisai president and COO Shaji Procida said: "We are grateful to our colleagues, each of whom has played an important role in helping us fulfill our human health care (hhc) mission of bringing important new medicines to patients.
"We are aware of the impact that our reorganization will have on some employees and will work with them to ensure that their transition is as smooth as possible."